Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Valencia – page 13

1 777 clinical trials in Valencia, Spain across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Valencia at a glance
1 777
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

1 777 trials in Valencia

Open in trial search

Renal cell carcinoma

Recruiting

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma+1

Recruiting

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Psoriatic arthropathy

Recruiting

Tulisokibart for Psoriatic Arthritis in Adults

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

HER2 positive breast cancer

Recruiting

Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:F. Hoffmann-La Roche AG

Pulmonary arterial hypertension

Recruiting

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Ductal adenocarcinoma of pancreas

Recruiting

A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:(12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
  • Sponsor:Revolution Medicines Inc.

Rheumatoid arthritis

Recruiting

A study to evaluate the effectiveness and safety of AZD1163 in adults with moderate to severe rheumatoid arthritis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD1163
  • Sponsor:AstraZeneca AB

Neoplasm malignant

Recruiting

A study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Colon cancer

Recruiting

A study to evaluate the safety and effectiveness of darizmetinib hydrochloride in patients who have had liver surgery due to colon cancer metastases

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Ovarian cancer

Recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Valencia

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focused on Mantle Cell Lymphoma treatments and Immune Thrombocytopenia, evaluating novel therapeutic combinations and investigating new treatment approaches.

  • Lymphoma therapies
  • Blood disorders
  • Immunotherapy combinations

Studies aim to improve treatment outcomes and provide alternative therapeutic options for patients.

02 Respiratory Medicine

Comprehensive studies addressing Respiratory Syncytial Virus, ARDS, and COPD, with focus on innovative treatments and preventive measures.

  • Viral respiratory infections
  • Acute respiratory conditions
  • Vaccine development

Research emphasizes both therapeutic interventions and preventive strategies for respiratory diseases.

03 Neurology & Stroke

Advanced research into acute ischemic stroke treatments and outcomes, investigating novel therapeutic approaches for better patient recovery.

  • Stroke treatment
  • Neurological recovery
  • Reperfusion therapies

Focus on improving functional outcomes and reducing complications in stroke patients.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.